Covariability of selected amino acid positions for HIV type 1 subtypes C and B

AIDS Research and Human Retroviruses

Volumn 21, Issue 12, 2005, Pages 1016-1030

  Gilbert, Peter B ^a,c   Novitsky, Vladimir ^b   Essex, Max ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Harvard AIDS Institute   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; EPITOPE; GAG PROTEIN; NEF PROTEIN; TRANSACTIVATOR PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1B; HUMAN IMMUNODEFICIENCY VIRUS 1C; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VIRUS MORPHOLOGY;

AMINO ACID SEQUENCE; AMINO ACIDS; GENE PRODUCTS, GAG; GENE PRODUCTS, NEF; GENE PRODUCTS, TAT; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNODOMINANT EPITOPES; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; SOFTWARE; STATISTICS, NONPARAMETRIC; VARIATION (GENETICS);

EID: 30344486956     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.1016     Document Type: Article

References (50)

1. Korber BT, Farber RM, Wolpert DH, and Lapedes AS: Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: An information theoretic analysis. Proc Natl Acad Sci USA 1993;90:7176-7180.
2. Bickel PJ, Cosman PC, Olshen RA, Spector PC, Rodrigo AG, and Mullins JI: Covariability of V3 loop amino acids. AIDS Res Hum Retroviruses 1996;12:1401-1411.
3. Brown AJ, Korber BT, and Condra JH: Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. AIDS Res Hum Retroviruses 1999;12:247-253.
4. Hoffman NG, Schiffer CA, and Swanstrom R: Covariation of amino acid positions in HIV-1 protease. Virology 2003;314:536-548.
5. Wu TD, Schiffer CA, Gonzales MJ, et al: Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003;77:4836-4847.
6. Gao F, Robertson DL, Carruthers CD, et al.: A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J Virol 1998;72:5680-5698.
7. Lole KS, Bollinger RC, Paranjape RS, et al: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73:152-160.
8. Ndung'u T, Renjifo B, Novitsky VA, McLane MF, Gaolekwe S, and Essex M: Molecular cloning and biological characterization of full-length HIV-1 subtype C from Botswana. Virology 2000;278: 390-399.
9. Novitsky V, Smith UR, Gilbert P, et al.: HIV-1 subtype C molecular phytogeny: Consensus sequence for an AIDS vaccine design? J Virol 2002;76:5435-5451.
10. Rodenburg CM, Li Y, Trask SA, et al.: Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses 2001;17:161-168.
11. Esparza J and Bhamarapravati N: Accelerating the development and future availability of HIV-1 vaccines: Why, when, where, and how? Lancet 2000;355:2061-2066.
12. Essex M: Human immunodeficiency viruses in the developing world. Adv Virus Res 1999;53:71-88.
13. Osmanov S, Pattou C, Walker N, Schwardlander B, and Esparza J: Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr Hum Retrovirol 2002;29:184-190.
14. UNAIDS and WHO: Global HIV/AIDS and STD surveillance. Epidemiological fact sheets by country. http:/www.who.int/emc-hiv/ fact sheets/, 2000.
15. Graham BS: Clinical trials of HIV vaccines. Ann Rev Med 2002; 53:207-221.
16. Nabel GJ: Challenges and opportunities for development of an AIDS vaccine. Nature 2001;410:1002-1007.
17. Korber BT, Brander C, Haynes B, Koup R, Kuiken C, Moore JP, Walker BD, and Watkins DI (eds.): HlV Molecular Immunology 2000. Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory, Los Alamos, NM, 2000.
18. Novitsky V, Rybak N, McLane MF, et al: Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific Elispot-based CTL responses for AIDS vaccine design. J Virol 2001;75:9210-9228.
19. Shiver JW, Fu TM, Chen L, et al.: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-335.
20. Korber BT, Foley BT, Kuiken CL, Pillai SK, and Sodroski JG: Numbering positions in HIV relative to HXB2CG. In: Human Retroviruses and AIDS 1998 (Korber B, Kuiken C, Foley B, Hahn B, McCutchan F, Mellors J, and Sodroski J, eds.). Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory, Los Alamos, NM, 1998, pp. III-102-III-111.
21. Bansal A, Sabbaj S, Edwards BH, Ritter D, Perkins C, Tang J, Szinger JJ, Weiss H, Goepfert PA, Korber B, Wilson CM, Kaslow RA, and Mulligan MJ: T cell responses in HIV type 1-infected adolescent minorities share similar epitope specificities with whites despite significant differences in HLA class I alleles. AIDS Res Hum Retroviruses 2003;19:1017-1026.
22. Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, and Goepfert PA: Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002;76:2298-2305.
23. Hill, WG: Tests for association of gene frequencies at several loci in random mating diploid populations. Biometrics 1975;31:881-888.
24. Goodman LA and Kruskal WH: Measures of Association for Cross Classification. Springer-Verlag, New York, 1979.
25. Weir BS and Cockerham CC: Testing hypotheses about linkage disequilibrium with multiple alleles. Genetics 1978;88:633-642.
26. Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
27. Gilbert PB, Rossini AJ, Shankarappa R; Two-sample tests for comparing intra-individual genetic sequence diversity between populations. Biometrics 2005;61:107-118.
28. Weir BS: Genetic Data Analysis. Sinauer, Sunderland, MA, 1990.
29. Park PJ and Kohane IS: Identifying three-way interactions among gene expression and chemosensitivity profiles using ternary mutual information. Technical report, Harvard University, Boston, MA, 2001.
30. Kosakovsky Pond SL and Frost SDW: Not so different after all: A comparison of methods for detecting amino acid sites under selection. Mol Biol Evol 2005;22:1208-1222.
31. Yang Z, Nielsen R, Goldman N, and Pedersen AM: Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics 2000;1:431-439.
32. Felsenstein J: PHYLIP: Phylogeny Inference Package, 3.572c. University of Washington, Seattle, WA, 1996.
33. Kuiken C, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, Mullins J, Wolinsky S, and Korber B (eds.): HIV Sequence Compendium 2000. Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory, Los Alamos, NM, 2000.
34. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, and Higgins DG: The ClustalX windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997;25:4876-4882.
35. Hall TA: BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999;41:95-98.
36. Goulder PJ, Brander C, Annamalai K, et al.: Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. J Virol 2000;74:5679-5690.
37. Piguet V and Trono D: A structure-function analysis of the Nef protein of primate lentiviruses. In: Human Retroviruses and AIDS 1999 (Kuiken C, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, Mullins J, Wolinsky S, and Korber B, eds.). Theoretical Biology and Biophysics, Group T-10, Los Alamos National Laboratory, Los Alamos, NM, 1999, pp. 448-459.
38. Mashishi T, Loubser S, Hide W, et al.: Conserved domains of subtype C Neffrom South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. AIDS Res Hum Retroviruses 2001;17:1681-1687.
39. Peyerl FW, Barouch DH, Yeh WW, et al.: Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope. J Virol 2003;77:12572-12578.
40. de Jong J-J, Goudsmit J, Keulen W, Klaver B, Krone W, Tersmette M, and de Ronde A: Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol 1992;66:757-765.
41. Chesebro B, Wehrly K, Nishio J, and Perryman S: Macrophagetropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell tropic isolates: Definition of critical amino acids involved in cell tropism. J Virol 1992;66:6547-6554.
42. Fouchier RAM, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Meidema F, and Schuitemaker H: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
43. Westervelt P, Trowbridge DB, Epstein LG, et-al.: Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo. J Virol 1992;66:2577-2582.
44. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, and Sodroski JG: A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998;280:1949-1953.
45. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, and Sodroski JG: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393:705-711.
46. Davis D, Stephens M, Willers C, and Lachmann PJ: Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J Gen Virol 1990;71:2889-2898.
47. Wei X, Decker JM, Wang S, et al.: Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.
48. Ping LH, Nelson JA, Hoffman IF, et al.: Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: Underrepresentation of X4 variants. J Virol 1999;73:6271-6281.
49. Tscherning C, Alaeus A, Fredriksson R, et al.: Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virol 1998;241:181-188.
50. Vranken WF, Budesinsky M, Fant F, Boulez K, and Borremans FA: The complete consensus V3 loop peptide of the envelope protein gp120 of HIV-1 shows pronounced helical character in solution. FEBS Lett 1995;374:117-121.